AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

L'Oréal

Earnings Release Aug 30, 2011

1467_iss_2011-08-30_d8bcde39-7814-4d32-af9a-d763663717bd.pdf

Earnings Release

Open in Viewer

Opens in native device viewer

First-half 2011 results

HISTORICALLY HIGH NET PROFIT*: 1,506 MILLION EUROS

Solid and good quality results:

  • Improvement in gross profit at 71.5%
  • Sustained investments in R&D and Advertising & Promotion
  • High operating margin, at 16.8% of sales
  • Net profit excluding non-recurring items after non-controlling interests: €1,506m, +6.7%
  • Net profit after non-controlling interests: +11.6%
  • EPS** at 2.52 euros: +5.4%

Confidence in the improvement of profitability for 2011.

Commenting on the figures, Mr Jean-Paul Agon, Chairman and CEO of L'Oréal, said:

"Organic growth in the first half of 2011 has confirmed the good dynamics of the group, which is further strengthening its worldwide positions, particularly in North America, in Latin America and in Asia Pacific.

The first-half results are up, solid and of good quality. Gross profit is improving, despite the higher cost of raw materials. Operating margin is at a high level, and net profit is growing strongly. At the same time we are continuing to pave the way for the future with our ongoing policy of sustained investments in R&D and advertising & promotion business drivers. Finally, the group's debt is particularly low.

These performances reflect the quality and solidity of the L'Oréal business model, based on powerful innovation, the vitality of our brand portfolio and a vast potential for internationalisation. In an uncertain economic environment, these fundamentals make us more confident than ever in the group's ability to build sustainable and profitable growth.

For 2011, we confirm our ambition to outperform the market and improve the group's profitability."

* net profit excluding non-recurring items after non-controlling interests.

** diluted net earnings per share, based on net profit excluding non-recurring items after non-controlling interests.

A – First-half 2011 sales

  • Based on reported figures, the group's sales, at June 30th, 2011, amounted to 10.15 billion euros, an increase of +5.0%. Like-for-like, i.e. based on a comparable structure and identical exchange rates, the sales growth of the L'Oréal group was +5.2%.The net impact of changes in consolidation was +0.7%. Currency fluctuations had a negative impact of -0.9%.Growth at constant exchange rates was +5.9%.
  • If the exchange rates at the end of July, i.e. €1 = \$1.438, are extrapolated up to December 31st, the impact of currency fluctuations on sales would be approximately -1.8% for the whole of 2011.
  • The news release of July 12th, 2011 details the activity for the first half of 2011. This news release is available and can be downloaded from the www.loreal-finance.com website.

Sales by operational division and geographic zone

nd quarter 2011
2
st half 2011
1
Growth Growth
€m Like-for-like Reported €m Like-for-like Reported
By operational division
Professional Products 704.6 1.2% -0.7% 1,420.2 2.1% 4.2%
Consumer Products 2,453.6 4.0% -0.2% 5,037.3 5.2% 4.5%
Luxury Products 1,133.3 9.5% 3.8% 2,249.8 8.5% 6.9%
Active Cosmetics 352.6 1.2% -0.9% 797.7 3.2% 3.2%
Cosmetics total 4,644.0 4.6% 0.6% 9,505.0 5.3% 4.9%
By geographic zone
Western Europe 1,854.9 1.2% 1.4% 3,765.3 0.8% 1.4%
North America 1,066.2 4.5% -4.9% 2,183.4 5.8% 3.1%
New Markets, of which: 1,722.9 8.6% 3.4% 3,556.3 10.1% 10.1%
- Asia Pacific 831.2 14.4% 8.1% 1,748.1 13.0% 13.5%
- Eastern Europe 325.3 -5.4% -8.2% 680.0 -3.4% -3.8%
- Latin America 427.1 11.7% 7.5% 830.7 17.3% 18.0%
- Africa, Middle East 139.4 4.3% -4.6% 297.6 10.1% 6.4%
Cosmetics total 4,644.0 4.6% 0.6% 9,505.0 5.3% 4.9%
The Body Shop 167.9 4.5% -1.3% 337.4 2.6% 0.9%
Dermatology(1) 177.5 4.9% 12.2% 307.2 5.3% 13.6%
Group total 4,989.4 4.6% 0.9% 10,149.6 5.2% 5.0%

(1) Group share, i.e. 50%.

B – First-half 2011: Solid and good quality results

The half-year consolidated accounts have undergone a limited examination by the Statutory Auditors.

1) Operating profitability at 16.8% of sales

Consolidated profit and loss accounts: from sales to operating profit.

In €m 06/30/10 As % of
sales
12/31/10 As % of
sales
06/30/11 As % of
sales
Growth
06/30/10
06/30/11
Sales 9,667 100% 19,496 100% 10,150 100% + 5.0%
Cost of sales -2,776 28.7% -5,697 29.2% -2,890 28.5% +4.1%
Gross Profit 6,890 71.3% 13,799 70.8% 7,260 71.5% +5.4%
R&D expenses -309 3.2% -665 3.4% -346 3.4% +12.2%
Advertising and promotion
expenses
-2,950 30.5% -6,029 30.9% -3,135 30.9% +6.3%
Selling, general and
administrative expenses
-1,963 20.3% -4,049 20.8% -2,076 20.5% +5.8%
Operating profit 1,669 17.3% 3,057 15.7% 1,702 16.8% +2.0%

Gross profit, at €7,260m, increased by 5.4%, and came out at 71.5% of sales, compared with 71.3% in the first half of 2010. Despite the unfavourable impact of higher raw materials prices, the improved efficiency and productivity of the factories, good stock management and finally the positive conversion effect, resulting from the strengthening of the euro, have contributed to this further improvement.

Research and development expenses have increased by 12.2%. This increase reflects the group's determination to step up its investments in Research and Innovation and, to a lesser extent, the integration of Q-Med.

Advertising and promotion expenses came out at 30.9% of sales, amounting to €3,135m, in line with the level for the full-year 2010.

Selling, general and administrative expenses amounted to €2,076m, representing 20.5% of sales, a level below that recorded in the full-year 2010.

Operating profit, at 16.8% of sales, amounted to €1,702m. This compares with the record level achieved in the first half of 2010 of 17.3%. The difference compared with the first half of 2010, that is 50 basis points, is the result of increased investments in R&D and advertising & promotion business drivers.

2) Operating profit by branch and division

06/30/10 12/31/10 06/30/11
€m % of sales €m % of sales €m % of sales
By operational division
Professional Products 288 21.2% 552 20.3% 281 19.8%
Consumer Products 982 20.4% 1,765 18.5% 1,013 20.1%
Luxury Products 378 18.0% 791 17.5% 426 18.9%
Active Cosmetics 208 26.9% 278 20.1% 210 26.3%
Cosmetics divisions total 1,856 20.5% 3,385 18.7% 1,930 20.3%
Non-allocated* -235 -2.6% -513 -2.8% -262 -2.8%
Cosmetics branch total 1,622 17.9% 2,872 15.8% 1,668 17.5%
The Body Shop 14 4.1% 65 8.7% 9 2.8%
Dermatology branch** 33 12.4% 119 19.8% 25 8.1%
Group 1,669 17.3% 3,057 15.7% 1,702 16.8%

* Non-allocated = Central group expenses, fundamental research expenses, stock option and free grant of shares expenses and miscellaneous items. As % of cosmetics sales.

** Group share, i.e. 50%.

The Professional Products Division is operating in a difficult market this year, and its profitability has edged down from 21.2% to 19.8%.

The profitability of the Consumer Products Division at 20.1% is slightly down on the first half of 2010, but is considerably higher than the full-year 2010 figure of 18.5%.

The profitability of the Luxury Products Division, at 18.9%, has grown strongly.

The Active Cosmetics Division has again recorded very high profitability at 26.3%.

The increase in non-allocated costs, at 2.8%, is mainly the result of the rise in Research expenses.

The profitability of The Body Shop, which is mainly achieved in the second half of each year, came out at 2.8%.

The decline in profitability of Dermatology is the result of two factors: firstly, competition from generics for Differin 0.1% gel and cream and for Loceryl and, secondly, negative exchange rate effects.

3) Net earnings per share*: €2.52

Consolidated profit and loss accounts, from operating profit to net profit excluding non-recurring items.

In €m 06/30/10 12/31/10 06/30/11 Evolution
06/30/10
06/30/11
Operating profit 1,669 3,057 1,702 +2.0%
Financial revenues and expenses excluding dividends
received
- 18 -36 -9
Sanofi dividends 284 284 296
Profit before tax excluding non-recurring items 1,935 3,305 1,989 +2.8%
Income tax excluding non-recurring items -522 -932 -481
Non-controlling interests -2 -2 -2
Net profit excluding non-recurring items after non
controlling interests *
1,411 2,371 1,506 +6.7%
Net EPS ** (€) 2.39 4.01 2.52 +5.4%
Net profit after non-controlling interests 1,314 2,240 1,467
Diluted net EPS after non-controlling interests (€) 2.23 3.79 2.46
Diluted average number of shares 589,549,689 591,392,449 596,970,041

* Net profit excluding non-recurring items after non-controlling interests does not include capital gains and losses on disposals of longterm assets, impairment of assets, restructuring costs, as well as competition litigation, and associated tax effects or non-controlling interests.

** Diluted net earnings per share excluding non-recurring items after non-controlling interests.

Overall finance costs, at €9m, have fallen sharply compared with the first half of 2010. This large reduction is the result of the significant decline in net debt.

The dividend received from Sanofi for 2010 amounted to €296m, an increase of +4.2%.

Profit before tax excluding non-recurring items amounted to €1,989m, an increase of +2.8%.

Income tax amounted to €481m, less than in the first half of 2010.

Net profit excluding non-recurring items after non-controlling interests amounted to €1,506m, up by +6.7%. EPS amounted to €2.52, up by +5.4% compared with the first half of 2010.

After allowing for non-recurring items, net profit after non-controlling interests amounted to €1,467m, an increase of +11.6%.

4) Stable operating cash flow and a robust balance sheet

Gross cash flow amounted to €1,795m, which is stable compared with the first half of 2010. The change in working capital has increased by €701m. The greater increase compared with the first half of 2010 stems mainly from the trade accounts payable and tax items.

Total cash flows from operating activities (see cash flow statement in Appendix VI) amounted to €1,094m.

Investments amounted to €400m that is approximately 4% of sales.

At June 30th, 2011, net financial debt totalled €526m. Gearing amounted to 3.3% of shareholders' equity.

The balance sheet structure, which was already robust, was further reinforced with shareholders' equity representing 64% of total assets.

"This news release does not constitute an off er t o sell, or a solicitation of a n of fer to buy L'Oréal s hares. If you wish to obtain more comprehensive information about L'Oréal, please ref er to the public documents registered in France with the Autorité des Marchés Financiers, also available in English on our Int ernet site www.loreal-finance.com.

This news release may contain some f orward -looking statements. Although the Company considers that these statements are based on reasonable hypot heses at the dat e of public ation of this release, they ar e by their nat ure s ubject to risks and uncert ainties which could cause actual results to differ materially from those indicat ed or projected in these statements."

Contacts at L'ORÉAL (Switchboard: +33 1 47 56 70 00)

Individual shareholders
and market authorities
Financial analysts and
Institutional investors
Journalists
Mr Jean Régis CAROF Mrs Françoise LAUVIN Mrs Stephanie CARSON-PARKER
Tel: +33 1 47 56 83 02
[email protected]
Tel: +33 1 47 56 86 82
[email protected]
Tel: +33 1 47 56 76 71
[email protected]

For more information, please contact your bank, broker or financial institution (I.S.I.N. code: F R0000120321), and consult your usual newspapers, and the Internet site for shareholders and investors, http://www.loreal-finance.com, or its mobile version on your cell phone, http://loreal-finance.mobi; alternatively, call +33 1 40 14 80 50

C – Appendices

I - Consolidated profit and loss accounts

€ millions st half 2011
1
st half 2010
1
2010
Net sales 10,149.6 9,666.8 19,495.8
Cost of sales -2,889.5 -2,776.3 -5,696.5
Gross profit 7,260.1 6,890.4 13,799.3
Research and development -346.3 -308.7 -664.7
Advertising and promotion -3,135.4 -2,950.4 -6,029.1
Selling, general and administrative expenses -2,076.1 -1,962.8 -4,048.6
Operating profit 1,702.3 1,668.6 3,056.9
Other income and expenses -62.6 -107.0 -153.2
Operational profit 1,639.7 1,561.5 2,903.7
Finance costs on gross debt -18.8 -23.5 -43.8
Finance income on cash and cash equivalents 12.7 9.2 17.2
Finance costs, net -6.1 -14.3 -26.6
Other financial income (expenses) -3.2 -3.5 -9.0
Sanofi dividends 295.6 283.8 283.8
Profit before tax and non-controlling interests 1,926.0 1,827.5 3,151.9
Income tax -457.9 -511.5 -909.9
Net profit 1,468.1 1,316.0 2,242.0
attributable to:
- owners of the company 1,466.6 1,314.3 2,239.7
- non-controlling interests 1.5 1.7 2.3
Earnings per share attributable to owners of the company (euros) 2.48 2.24 3.82
Diluted earnings per share attributable to owners of the company (euros) 2.46 2.23 3.79
Earnings per share attributable to owners of the company excluding non
recurring items (euros)
2.55 2.41 4.04
Diluted earnings per share attributable to owners of the company
excluding non-recurring items (euros)
2.52 2.39 4.01

II - Consolidated statements of net profit and gains and losses directly recognised in equity

€ millions st half 2011
1
st half 2010
1
2010
Consolidated net profit for the period 1,468.1 1,316.0 2,242.0
Financial assets available for sale 896.7 -653.8 -852.3
Cash flow hedges 37.7 -81.0 -8.0
Actuarial gains and losses -1.0 -0.4 -213.5
Tax effect on items directly recognised in equity (1) -25.8 32.8 92.0
Cumulative translation adjustments -359.5 798.4 463.3
Changes in gains and losses directly recognised in equity 548.1 96.0 -518.5
Total net profit and gains and losses directly recognised in equity 2,016.2 1,412.0 1,723.5
Attributable to:
- owners of the company 2,014.6 1,410.3 1,721.2
- non-controlling interests 1.6 1.7 2.3

(1) The tax effect is as follows:

€ millions st half 2011
1
st half 2010
1
2010
Financial assets available for sale -15.2 11.3 14.6
Cash flow hedges -10.8 21.3 1.1
Actuarial gains and losses 0.2 0.2 76.3
Total -25.8 32.8 92.0

III - Consolidated balance sheets

Assets

€ millions 06.30.2011 06.30.2010 12.31.2010
Non-current assets 17,945.8 17,605.6 17,048.2
Goodwill 5,705.9 5,894.9 5,729.6
Other intangible assets 2,232.0 2,297.0 2,177.5
Tangible assets 2,672.0 2,780.0 2,677.5
Non-current financial assets 6,729.0 6,043.9 5,837.5
Deferred tax assets 606.9 589.8 626.1
Current assets 7,230.2 7,160.0 6,996.3
Inventories 1,896.0 1,766.6 1,810.1
Trade accounts receivable 3,049.9 3,077.5 2,685.3
Other current assets 969.9 833.8 846.0
Current tax assets 60.0 48.1 104.5
Cash and cash equivalents 1,254.4 1,434.0 1,550.4
Total 25,176.0 24,765.6 24,044.5

Equity & Liabilities

€ millions 06.30.2011 06.30.2010 12.31.2010
Equity 16,118.3 14,254.3 14,865.8
Share capital 120.5 119.9 120.2
Additional paid-in capital 1,251.2 1,053.9 1,148.3
Other reserves 12,322.5 11,052.9 11,107.1
Items directly recognised in equity 2,095.6 1,467.6 1,188.1
Cumulative translation adjustments -449.1 245.4 -89.6
Treasury stock -691.3 -1,002.5 -850.9
Net profit attributable to owners of the company 1,466.6 1,314.3 2,239.7
Equity attributable to owners of the company 16,116.0 14,251.5 14,862.9
Non-controlling interests 2.3 2.8 2.9
Non-current liabilities 1,854.5 2,593.5 2,596.6
Provisions for employee retirement and obligations and related benefits 1,012.0 1,006.4 1,129.0
Provisions for liabilities and charges 172.6 163.2 181.3
Deferred tax liabilities 506.1 429.4 462.0
Non-current borrowings and debt 163.8 994.5 824.3
Current liabilities 7,203.2 7,917.8 6,582.1
Trade accounts payable 2,997.3 2,950.1 3,153.5
Provisions for liabilities and charges 517.0 602.8 536.9
Other current liabilities 1,905.8 2,039.2 1,958.1
Income tax 166.4 213.4 166.6
Current borrowings and debt 1,616.7 2,112.3 767.0
Total 25,176.0 24,765.6 24,044.5

IV - Consolidated statements of changes in equity

Common
shares
Share Additional
paid-in
Retained
earnings
and net
Items
directly
recognised
Treasury Cumulative
translation
Equity
attributable
to owners
of the
Non
controlling
Total
€ millions
At 12.31.2009
outstanding
584,735,660
capital
119.8
capital
996.5
profit
11,933.5
in equity
2,169.9
stock
-1,071.6
adjustments
-552.9
company
13,595.2
interests
3.1
equity
13,598.3
Consolidated net profit for the period 2,239.7 2,239.7 2.3 2,242.0
Financial assets available for sale -837.7 -837.7 -837.7
Cash flow hedges -6.8 -6.8 -6.8
Actuarial gains and losses -137.3 -137.3 -137.3
Cumulative translation adjustments 463.3 463.3 463.3
Change in gains and losses directly
recognised in equity
-981.8 463.3 -518.5 - -518.5
Total net profit and gains and
losses directly recognised in equity
2,239.7 -981.8 463.3 1,721.2 2.3 1,723.5
Capital increase 2,520,175 0.5 151.8 152.3 152.3
Cancellation of treasury stock -0.1 -37.8 37.9 - -
Dividends paid
(not paid on treasury stock)
-878.8 -878.8 -2.2 -881.0
Share-based payment 84.8 84.8 84.8
Net changes in treasury stock 2,400,068 1.1 182.8 183.9 183.9
Purchase of non-controlling interests -2.9 -2.9 -2.9
Other movements 7.2 7.2 -0.3 6.9
At 12.31.2010 589,655,903 120.2 1,148.3 13,346.8 1,188.1 -850.9 -89.6 14,862.9 2.9 14,865.8
Consolidated net profit for the period 1,466.6 1,466.6 1.5 1,468.1
Financial assets available for sale 881.5 881.5 881.5
Cash flow hedges 26.8 26.8 0.1 26.9
Actuarial gains and losses -0.8 -0.8 -0.8
Cumulative translation adjustments -359.5 -359.5 -359.5
Change in gains and losses directly
recognised in equity
907.5 -359.5 548.0 0.1 548.1
Total net profit and gains and
losses directly recognised in equity
1,466.6 907.5 -359.5 2,014.6 1.6 2,016.2
Capital increase 1,661,947 0.3 102.9 103.2 103.2
Cancellation of treasury stock - -
Dividends paid
(not paid on treasury stock)
-1,065.3 -1,065.3 -1.9 -1,067.2
Share-based payment 39.0 39.0 39.0
Net changes in treasury stock 2,106,656 1.3 159.6 160.9 160.9
Purchase of non-controlling interests - -
Other movements 0.7 0.7 -0.3 0.4
At 06.30.2011 593,424,506 120.5 1,251.2 13,789.1 2,095.6 -691.3 -449.1 16,116.0 2.3 16,118.3

V - Changes in first half 2010

Equity
Retained Items attributable
Common Additional earnings directly Cumulative to owners Non
shares Share paid-in and net recognised Treasury translation of the controlling Total
€ millions outstanding capital capital profit in equity stock adjustments company interests equity
At 12.31.2009 584,735,660 119.8 996.5 11,933.5 2,169.9 -1,071.6 -552.9 13,595.2 3.1 13,598.3
Consolidated net profit for the period 1,314.3 1,314.3 1.7 1,316.0
Financial assets available for sale -642.5 -642.5 -642.5
Cash flow hedges -59.6 -59.6 -0.1 -59.7
Actuarial gains and losses -0.2 -0.2 -0.2
Cumulative translation adjustments 798.3 798.3 0.1 798.4
Change in gains and losses directly
recognised in equity
-702.3 798.3 96.0 - 96.0
Total net profit and gains and
losses directly recognised in equity 1,314.3 -702.3 798.3 1,410.3 1.7 1,412.0
Capital increase 959,950 0.2 57.4 57.6 57.6
Cancellation of treasury stock -0.1 -37.8 37.9 - -
Dividends paid
(not paid on treasury stock)
-878.8 -878.8 -2.0 -880.8
Share-based payment 38.7 38.7 38.7
Net changes in treasury stock 460,700 0.4 31.2 31.6 31.6
Purchase of non-controlling interests -3.1 -3.1 -3.1
Other movements - -
At 06.30.2010 586,156,310 119.9 1,053.9 12,367.2 1,467.6 -1,002.5 245.4 14,251.5 2.8 14,254.3

VI - Consolidated statements of cash flows

€ millions st half 2011
1
st half 2010
1
2010
Cash flows from operating activities
Net profit attributable to owners of the company 1,466.6 1,314.3 2,239.7
Non-controlling interests 1.5 1.7 2.3
Elimination of expenses and income with no impact on cash flows:
• depreciation, amortisation and provisions 276.7 398.6 734.2
• changes in deferred taxes 14.2 39.4 110.0
• share-based payment 39.0 38.7 84.8
• capital gains and losses on disposals of assets -3.1 -0.4 0.1
Gross cash flow 1,795.0 1,792.3 3,171.1
Changes in working capital -701.1 -289.2 132.5
Net cash provided by operating activities (A) 1,093.9 1,503.1 3,303.6
Cash flows from investing activities
Investments in tangible and intangible assets -400.2 -320.9 -677.9
Disposal of tangible and intangible assets 7.1 6.0 18.3
Changes in other financial assets
(including investments in non-consolidated companies)
-3.9 11.7 2.3
Effect of changes in the scope of consolidation -330.9 -124.3 -160.7
Net cash (used in) from investing activities (B) -727.9 -427.5 -818.0
Cash flows from financing activities
Dividends paid -1,096.8 -896.4 -921.6
Capital increase of the Parent Company 103.2 57.6 152.3
Disposal (acquisition) of treasury stock 160.9 31.6 184.0
Purchase of non-controlling interests - -8.4 -8.7
Issuance (repayment) of short-term loans 628.2 -9.6 -132.6
Issuance of long-term borrowings - - 4.0
Repayment of long-term borrowings -411.0 -101.6 -1,462.5
Net cash (used in) from financing activities (C) -615.4 -926.8 -2,185.1
Net effect of changes in exchange rates and fair value (D) -46.6 112.1 76.9
Change in cash and cash equivalents (A+B+C+D) -296.0 260.9 377.4
Cash and cash equivalents at beginning of the year (E) 1,550.4 1,173.1 1,173.1
Cash and cash equivalents at end of the period (A+B+C+D+E) 1,254.4 1,434.0 1,550.4

Talk to a Data Expert

Have a question? We'll get back to you promptly.